ASCO

#ASCO26 truly embodied the theme of translating science into global patient outcomes. We are grateful to the ~46,000 attendees, all working tirelessly to conquer cancer together! A heartfelt thanks to all. 💗 We can’t wait to see you next year at #ASCO27!

Our draft guideline recommendations for “Management of Immune-Related Adverse Events- neurologic, and dermatologic toxicities, and adverse events from steroids recommendations” are now open for public comment.

Submit your comments to us by November 20: bit.ly/4eejJYR

Final rules for Medicare reimbursement in 2027 implement a 2% cut to physician payments & changes to reimbursement for hospital outpatient services.

We’re assessing the full impact on cancer care, but our initial analysis is out: bit.ly/4kkFxWH
#ASCOAdvocacy

🎙 @montypal of @cityofhope and @MarcoRuella of @PennMedicine break down landmark 10-year tisa-cel data in B-cell lymphomas, next-gen dual-targeted CARs, and the shift into earlier lines of treatment on a new episode of the #ASCODailyNews Podcast: bit.ly/4AeUzlm

New #BreastCancer research funding is open from @ConquerCancerFd! Whether you're launching an independent lab, leading original trials, or mentoring future leaders, 3 new global grants are accepting submissions.

🌍 U.S. & Global applicants welcome: bit.ly/3UXTuPS